Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GMALL treatment optimization trial in newly diagnosed adult ALL or lymphoblastic lymphoma with phase III evaluation of nelarabine in T-ALL
2013-003466-13Phase 3Completed
- Sponsor
- Goethe University Frankfurt
- Start
- May 2015
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of nelarabine and pegaspargase in acute lymphoblastic leukemia (ALL), lymphoblastic lymphoma (LL) and t-cell acute lymphoblastic leukemia (T-ALL) (2 arms), sponsored by Goethe University Frankfurt. Primary endpoint: Event-free survival. Started May 2015; status: completed.
02
Drugs
nelarabinepegaspargase
03
Conditions
acute lymphoblastic leukemia (ALL)lymphoblastic lymphoma (LL)t-cell acute lymphoblastic leukemia (T-ALL)
Beyond the preview
Go deeper on 2013-003466-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003466-13.